CLAIMS

1. Use of andrographolide as an active ingredient, for preventing fatigue, reducing fatigue, or recovering from fatigue.

2. Use of Claim 1, wherein andrographolide is contained in a food, or a drink.

3. Use of Claim 2, wherein the fatigue is selected from the group consisting of chronic fatigue syndrome, overwork, physical fatigue, mental fatigue, and organ fatigue.

4. Use of any one of Claims 1-3, wherein a daily amount of andrographolide to be taken by an animal including a human is 0.01-500 mg per kilogram of body weight.

5. Use of any one of Claims 1-3, wherein a daily amount of andrographolide to be taken by human adult is 0.1-100 mg.

6. Use of any one of Claims 1-5, in combination with alpha-lipoic acid.

7. Use of Claim 6, wherein a daily amount of andrographolide to be taken by an animal including a human is 0.01-500 mg per kilogram of body weight and 1-200 mg of the alpha-lipoic acid per kilogram of body weight.

8. Use of Claim 6, wherein a daily amount of andrographolide to be taken by a human adult is 0.1-100 mg of the andrographolide and 10-400 mg of the alpha-lipoic acid.


9. Use of any one of Claims 1-8, which is to be taken a single time, multiple times, or on a regular basis.

10. Use of any one of Claims 1-9, wherein andrographolide is used as an additive for a feed for an animal, an additive for a drink for an animal, a feed for an animal, or a drink for an animal.

11. Andrographolide for use in a method for preventinve or treating a fatigue-related illness or condition.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. The use of andrographolide, which is a compound represented by formula (I):



(I)

and alpha-lipoic acid, as active ingredients, for preventing fatigue, reducing fatigue, or recovering from fatigue.

2. The use according to Claim 1, wherein andrographolide and alpha-lipoic acid are contained in a food, or a drink.

3. The use according to Claim 1 or Claim 2, wherein the fatigue is selected from the group consisting of chronic fatigue syndrome, overwork, physical fatigue, mental fatigue, and organ fatigue.

4. The use according to any one of Claims 1 to 3, wherein a daily amount of andrographolide to be taken by an animal is 0.01-500 mg per kilogram of body weight.

5. The use according to Claim 4, wherein said animal is a human.

6. The use according to Claim 5, wherein a daily amount of andrographolide to be taken by a human adult is 0.1-100 mg.

7. The use according to any one of Claims 1 to 3, wherein a daily amount of andrographolide to be taken by an animal is 0.01-500 mg per kilogram of body weight and 1-200 mg of the alpha-lipoic acid per kilogram of body weight.


8. The use according to Claim 7, wherein the animal is a human.

9. The use according to any one of Claims 1 to 3, wherein a daily amount of andrographolide to be taken by a human adult is 0.1-100 mg of the andrographolide and 10-400 mg of the alpha-lipoic acid.

10. The use according to any one of Claims 1 to 9, wherein the andrographolide and alpha-lipoic acid are to be taken a single time, multiple times, or on a regular basis.

11. The use according to Claim 2, wherein andrographolide and alpha-lipoic acid are used as additives for a feed for an animal, an additive for a drink for an animal, a feed for an animal, or a drink for an animal.

12. Andrographolide, which is a compound represented by Formula (I):



(I)

and alpha-lipoic acid for use in the treatment of a fatigue-relatedness illness or condition.